MDICT Task Force
The Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT) is an international task force of leading phase 1 investigators and senior industry employees in charge of the clinical development of anticancer agents. MDICT's mission is to develop practical guidance for the optimal development of innovative anticancer agents, in particular targeted agents. The group is chaired by drs. Elizabeth Eisenhauer (Canada), Giuseppe Giaccone (USA) and Hilary Calvert (UK), and is supported by the NDDO Education Foundation (represented by Marinus Lobbezoo, The Netherlands), the primary organizer of the TAT Congress series. Verbal reports of MDICT Task Force meetings are always presented in a plenary sesssion of the ensuing TAT congress. These presentations are accessible via the "TAT slides" buttons on the right hand side of this page. Several MDICT reports have been published in full (see below).
Annual meetings
The Task Force meets annually in conjunction with the TAT meeting. However, no MDICT meeting is for TAT 2013 in Paris, March 4-6.
Joining MDICT
Participation in MDICT meetings is by personal invitation only. Professionals with a relevant role in oncology drug development in academia, industry, governmental or regulatory agencies are welcome to participate. If you are interested in joining, submit your CV and a brief motivation to the TAT Secretariat (
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
).
MDICT reports
Reports of MDICT meetings held in 2006 - 2012 have been published (1-5). Papers on the outcomes of the 2011 and 2012 meetings are under preparation. A review of the first years of MDICT has been published (6).
1. Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA. Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 2008;44:19-24. Abstract.
2. Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Eisenhauer EA, Seymour LK. Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 2008;44:25-29. Abstract.
3. Kummar S, Doroshow JH, Tomaszewski JE, Calvert AH, Lobbezoo M, Giaccone G. Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer 2009;45:741-746. Abstract.
4. Goodwin R, Giaccone G, Calvert H, Lobezoo M, Eisenhauer EA. Targeted agents: How to select the winners in preclinical and early clinical studies? Eur J Cancer 2011. Abstract.
5. Seymour LK, Calvert AH, Lobbezoo MW, Eisenhauer EA, Giaccone G. Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer 2013. http://dx.doi.org/10.1016/j.ejca.2013.01.014
6. Lobbezoo MW, Calvert AH, Eisenhauer EA, Giaccone G. MDICT Task Force addresses methodological issues in the clinical development of innovative cancer therapies. Clinical Invest 2012;2(2):133–138.
